Cargando…
Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial
BACKGROUND: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449994/ https://www.ncbi.nlm.nih.gov/pubmed/30947693 http://dx.doi.org/10.1186/s12879-019-3920-8 |
_version_ | 1783408966470991872 |
---|---|
author | El Guerche-Séblain, Clotilde Moureau, Annick Schiffler, Camille Dupuy, Martin Pepin, Stephanie Samson, Sandrine I. Vanhems, Philippe Schellevis, François |
author_facet | El Guerche-Séblain, Clotilde Moureau, Annick Schiffler, Camille Dupuy, Martin Pepin, Stephanie Samson, Sandrine I. Vanhems, Philippe Schellevis, François |
author_sort | El Guerche-Séblain, Clotilde |
collection | PubMed |
description | BACKGROUND: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. METHODS: This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. RESULTS: Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. CONCLUSIONS: Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. TRIAL REGISTRATION: EudraCT no. 2013–001231-51. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-019-3920-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6449994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64499942019-04-16 Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial El Guerche-Séblain, Clotilde Moureau, Annick Schiffler, Camille Dupuy, Martin Pepin, Stephanie Samson, Sandrine I. Vanhems, Philippe Schellevis, François BMC Infect Dis Research Article BACKGROUND: Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres. METHODS: This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza. RESULTS: Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes. CONCLUSIONS: Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza. TRIAL REGISTRATION: EudraCT no. 2013–001231-51. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-019-3920-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-04 /pmc/articles/PMC6449994/ /pubmed/30947693 http://dx.doi.org/10.1186/s12879-019-3920-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article El Guerche-Séblain, Clotilde Moureau, Annick Schiffler, Camille Dupuy, Martin Pepin, Stephanie Samson, Sandrine I. Vanhems, Philippe Schellevis, François Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title | Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_full | Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_fullStr | Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_full_unstemmed | Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_short | Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial |
title_sort | epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase iii efficacy trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449994/ https://www.ncbi.nlm.nih.gov/pubmed/30947693 http://dx.doi.org/10.1186/s12879-019-3920-8 |
work_keys_str_mv | AT elguercheseblainclotilde epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT moureauannick epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT schifflercamille epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT dupuymartin epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT pepinstephanie epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT samsonsandrinei epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT vanhemsphilippe epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial AT schellevisfrancois epidemiologyandburdenofinfluenzainhealthychildrenaged6to35monthsanalysisofdatafromtheplaceboarmofaphaseiiiefficacytrial |